We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
What's in the Offing for Baxter's (BAX) Earnings in Q3?
Read MoreHide Full Article
Baxter International Inc. (BAX - Free Report) is scheduled to release third-quarter 2019 results on Oct 24, before the opening bell. In the last reported quarter, the company delivered a positive earnings surprise of 9.9%. Further, it has an average four-quarter positive surprise of 9.2%.
Which Way Are Estimates Treading?
Currently, the Zacks Consensus Estimate for third-quarter revenues is pegged at $2.86 billion, suggesting growth of 3.5% from the year-ago reported number. The consensus estimates for earnings is pegged at 84 cents per share, indicating an improvement of 5% from the prior-year quarter.
New product launches and the ongoing rollout of PrisMax next-generation technology for continuous renal replacement therapy (CRRT) and Therapeutic Plasma Exchange is likely to have contributed to Baxter’s Acute Therapies business and consequently the segment’s top line in the third quarter. Additionally, continued focus on geographic expansion is anticipated to get reflected in the to-be-reported quarter’s revenues.
In fact, the Zacks Consensus Estimate for the segment’s third-quarter revenues is pegged at $134 million, indicating year-over-year growth of 9.8%.
Further, growing demand for Baxter’s Spectrum IQ and Evo IQ infusion pumps is likely to have impacted third-quarter performance.
The top line is anticipated to have benefited from Baxter’s strong product portfolio, and the planned launch of therapies and products, the company.
With respect to international sales, the company has likely to have experienced higher volume of the same driven by the rising demand of its hospital pharmacy compounding services, generic injectables and anesthesia products.
However, Baxter’s Pharmaceutical business faces increasing generic competition for cyclophosphamide and Brevibloc.
Moreover, headwinds related to Baxter’s U.S. business and exit of the in-center hemo dialysis Bloodline business are likely to have affected the core Renal Care arm. In fact, management expects the business’ exit to negatively impact Baxter’s Renal Care sales in 2019 by approximately $55 million. Notably, the Zacks Consensus Estimate for the segment’s third-quarter revenues is pegged at $910 million, remaining flat from the year-ago quarter.
What Our Quantitative Model Suggests
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below.
Earnings ESP: Baxter has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Baxter carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
AmerisourceBergen Corporation has an Earnings ESP of +0.55% and a Zacks Rank #3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.50% and a Zacks Rank #3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
Image: Bigstock
What's in the Offing for Baxter's (BAX) Earnings in Q3?
Baxter International Inc. (BAX - Free Report) is scheduled to release third-quarter 2019 results on Oct 24, before the opening bell. In the last reported quarter, the company delivered a positive earnings surprise of 9.9%. Further, it has an average four-quarter positive surprise of 9.2%.
Which Way Are Estimates Treading?
Currently, the Zacks Consensus Estimate for third-quarter revenues is pegged at $2.86 billion, suggesting growth of 3.5% from the year-ago reported number. The consensus estimates for earnings is pegged at 84 cents per share, indicating an improvement of 5% from the prior-year quarter.
Baxter International Inc. Price and EPS Surprise
Baxter International Inc. price-eps-surprise | Baxter International Inc. Quote
Factors to Influence Q3
New product launches and the ongoing rollout of PrisMax next-generation technology for continuous renal replacement therapy (CRRT) and Therapeutic Plasma Exchange is likely to have contributed to Baxter’s Acute Therapies business and consequently the segment’s top line in the third quarter. Additionally, continued focus on geographic expansion is anticipated to get reflected in the to-be-reported quarter’s revenues.
In fact, the Zacks Consensus Estimate for the segment’s third-quarter revenues is pegged at $134 million, indicating year-over-year growth of 9.8%.
Further, growing demand for Baxter’s Spectrum IQ and Evo IQ infusion pumps is likely to have impacted third-quarter performance.
The top line is anticipated to have benefited from Baxter’s strong product portfolio, and the planned launch of therapies and products, the company.
With respect to international sales, the company has likely to have experienced higher volume of the same driven by the rising demand of its hospital pharmacy compounding services, generic injectables and anesthesia products.
However, Baxter’s Pharmaceutical business faces increasing generic competition for cyclophosphamide and Brevibloc.
Moreover, headwinds related to Baxter’s U.S. business and exit of the in-center hemo dialysis Bloodline business are likely to have affected the core Renal Care arm. In fact, management expects the business’ exit to negatively impact Baxter’s Renal Care sales in 2019 by approximately $55 million. Notably, the Zacks Consensus Estimate for the segment’s third-quarter revenues is pegged at $910 million, remaining flat from the year-ago quarter.
What Our Quantitative Model Suggests
Per our proven model, a stock needs to have a positive Earnings ESP and a Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) to deliver a positive earnings surprise. This is not the case here as you will see below.
Earnings ESP: Baxter has an Earnings ESP of 0.00%. You can uncover the best stocks to buy or sell before they’re reported with our Earnings ESP Filter.
Zacks Rank: Baxter carries a Zacks Rank #3.
Stocks Worth a Look
Here are a few medical stocks worth considering as they have the right combination of elements to post an earnings beat this quarter.
Edward Lifesciences Corporation (EW - Free Report) has an Earnings ESP of +0.35% and a Zacks Rank #3. You can see the complete list of today’s Zacks #1 Rank stocks here.
AmerisourceBergen Corporation has an Earnings ESP of +0.55% and a Zacks Rank #3.
Cardinal Health, Inc. (CAH - Free Report) has an Earnings ESP of +1.50% and a Zacks Rank #3.
Biggest Tech Breakthrough in a Generation
Be among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.
A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 7 stocks to watch. The report is only available for a limited time.
See 7 breakthrough stocks now>>